398 related articles for article (PubMed ID: 25536881)
1. The fibrate gemfibrozil is a NO- and haem-independent activator of soluble guanylyl cyclase: in vitro studies.
Sharina IG; Sobolevsky M; Papakyriakou A; Rukoyatkina N; Spyroulias GA; Gambaryan S; Martin E
Br J Pharmacol; 2015 May; 172(9):2316-29. PubMed ID: 25536881
[TBL] [Abstract][Full Text] [Related]
2. Distinct molecular requirements for activation or stabilization of soluble guanylyl cyclase upon haem oxidation-induced degradation.
Hoffmann LS; Schmidt PM; Keim Y; Schaefer S; Schmidt HH; Stasch JP
Br J Pharmacol; 2009 Jul; 157(5):781-95. PubMed ID: 19466990
[TBL] [Abstract][Full Text] [Related]
3. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease.
Boerrigter G; Burnett JC
Cardiovasc Drug Rev; 2007; 25(1):30-45. PubMed ID: 17445086
[TBL] [Abstract][Full Text] [Related]
4. NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle.
Stasch JP; Schmidt P; Alonso-Alija C; Apeler H; Dembowsky K; Haerter M; Heil M; Minuth T; Perzborn E; Pleiss U; Schramm M; Schroeder W; Schröder H; Stahl E; Steinke W; Wunder F
Br J Pharmacol; 2002 Jul; 136(5):773-83. PubMed ID: 12086987
[TBL] [Abstract][Full Text] [Related]
5. NO- and haem-independent soluble guanylate cyclase activators.
Schmidt HH; Schmidt PM; Stasch JP
Handb Exp Pharmacol; 2009; (191):309-39. PubMed ID: 19089335
[TBL] [Abstract][Full Text] [Related]
6. Activation of haem-oxidized soluble guanylyl cyclase with BAY 60-2770 in human platelets lead to overstimulation of the cyclic GMP signaling pathway.
Mendes-Silverio CB; Leiria LO; Morganti RP; Anhê GF; Marcondes S; Mónica FZ; De Nucci G; Antunes E
PLoS One; 2012; 7(11):e47223. PubMed ID: 23144808
[TBL] [Abstract][Full Text] [Related]
7. NO-independent, haem-dependent soluble guanylate cyclase stimulators.
Stasch JP; Hobbs AJ
Handb Exp Pharmacol; 2009; (191):277-308. PubMed ID: 19089334
[TBL] [Abstract][Full Text] [Related]
8. Reduced vascular responses to soluble guanylyl cyclase but increased sensitivity to sildenafil in female rats with type 2 diabetes.
Goulopoulou S; Hannan JL; Matsumoto T; Ogbi S; Ergul A; Webb RC
Am J Physiol Heart Circ Physiol; 2015 Jul; 309(2):H297-304. PubMed ID: 25957216
[TBL] [Abstract][Full Text] [Related]
9. Gemfibrozil derivatives as activators of soluble guanylyl cyclase - A structure-activity study.
Gayler KM; Quintana JM; Mattke J; Plunk MA; Kostyo JH; Karunananthan JW; Nguyen H; Shuda M; Ferreira LD; Baker H; Stinchcomb AL; Sharina I; Kane RR; Martin E
Eur J Med Chem; 2021 Nov; 224():113729. PubMed ID: 34365128
[TBL] [Abstract][Full Text] [Related]
10. Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition.
Fraccarollo D; Galuppo P; Motschenbacher S; Ruetten H; Schäfer A; Bauersachs J
Basic Res Cardiol; 2014 Jul; 109(4):421. PubMed ID: 24907870
[TBL] [Abstract][Full Text] [Related]
11. Effects of peroxynitrite on relaxation through the NO/sGC/cGMP pathway in isolated rat iliac arteries.
Tawa M; Shimosato T; Iwasaki H; Imamura T; Okamura T
J Vasc Res; 2014; 51(6):439-46. PubMed ID: 25634663
[TBL] [Abstract][Full Text] [Related]
12. NO-independent stimulation or activation of soluble guanylyl cyclase during early reperfusion limits infarct size.
Bice JS; Keim Y; Stasch JP; Baxter GF
Cardiovasc Res; 2014 Feb; 101(2):220-8. PubMed ID: 24259501
[TBL] [Abstract][Full Text] [Related]
13. Fluorescence dequenching makes haem-free soluble guanylate cyclase detectable in living cells.
Hoffmann LS; Schmidt PM; Keim Y; Hoffmann C; Schmidt HH; Stasch JP
PLoS One; 2011; 6(8):e23596. PubMed ID: 21858179
[TBL] [Abstract][Full Text] [Related]
14. Nitric oxide- and heme-independent activation of soluble guanylate cyclase attenuates peroxynitrite-induced endothelial dysfunction in rat aorta.
Korkmaz S; Loganathan S; Mikles B; Radovits T; Barnucz E; Hirschberg K; Li S; Hegedüs P; Páli S; Weymann A; Karck M; Szabó G
J Cardiovasc Pharmacol Ther; 2013 Jan; 18(1):70-7. PubMed ID: 22914857
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular and pharmacological implications of haem-deficient NO-unresponsive soluble guanylate cyclase knock-in mice.
Thoonen R; Cauwels A; Decaluwe K; Geschka S; Tainsh RE; Delanghe J; Hochepied T; De Cauwer L; Rogge E; Voet S; Sips P; Karas RH; Bloch KD; Vuylsteke M; Stasch JP; Van de Voorde J; Buys ES; Brouckaert P
Nat Commun; 2015 Oct; 6():8482. PubMed ID: 26442659
[TBL] [Abstract][Full Text] [Related]
16. A new small molecule inhibitor of soluble guanylate cyclase.
Mota F; Gane P; Hampden-Smith K; Allerston CK; Garthwaite J; Selwood DL
Bioorg Med Chem; 2015 Sep; 23(17):5303-10. PubMed ID: 26264842
[TBL] [Abstract][Full Text] [Related]
17. Nitric oxide-independent vasodilator rescues heme-oxidized soluble guanylate cyclase from proteasomal degradation.
Meurer S; Pioch S; Pabst T; Opitz N; Schmidt PM; Beckhaus T; Wagner K; Matt S; Gegenbauer K; Geschka S; Karas M; Stasch JP; Schmidt HH; Müller-Esterl W
Circ Res; 2009 Jul; 105(1):33-41. PubMed ID: 19478201
[TBL] [Abstract][Full Text] [Related]
18. Pharmacology of the nitric oxide receptor, soluble guanylyl cyclase, in cerebellar cells.
Bellamy TC; Garthwaite J
Br J Pharmacol; 2002 May; 136(1):95-103. PubMed ID: 11976273
[TBL] [Abstract][Full Text] [Related]
19. Soluble guanylyl cyclase activation by HMR-1766 (ataciguat) in cells exposed to oxidative stress.
Zhou Z; Pyriochou A; Kotanidou A; Dalkas G; van Eickels M; Spyroulias G; Roussos C; Papapetropoulos A
Am J Physiol Heart Circ Physiol; 2008 Oct; 295(4):H1763-71. PubMed ID: 18757489
[TBL] [Abstract][Full Text] [Related]
20. Guanylyl cyclase activator ataciguat improves vascular function and reduces platelet activation in heart failure.
Schäfer A; Fraccarollo D; Werner L; Bauersachs J
Pharmacol Res; 2010 Nov; 62(5):432-8. PubMed ID: 20600916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
